Thomas Radimerski

Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue

Joseph Schoepfer, Pascal Furet, R. Schmitz, 2009, BMC Chemical Biology.

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.

Sebastian Uhrig, Mauro Delorenzi, Vaskar Saha, 2017, Blood.

Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.

Eric Vangrevelinghe, Clive McCarthy, Pascal Furet, 2010, Bioorganic & medicinal chemistry letters.

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

Jonathan J. Chen, Franziska Michor, Omar Abdel-Wahab, 2015, Cancer discovery.

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

Joseph Schoepfer, Michael Rugaard Jensen, Robert Cozens, 2008, Breast Cancer Research.

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Eric Vangrevelinghe, Andrew L. Kung, James E. Bradner, 2011, The Journal of experimental medicine.

2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.

Eric Vangrevelinghe, Marc Lang, Pascal Furet, 2010, Bioorganic & medicinal chemistry letters.